BTOG shared a post on X:
“Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy
BTOG wishes to inform members of a new NICE release that has been published today.
NICE has recommended osimertinib, within its marketing authorisation, as an option to treat unresectable locally advanced (stage 3) non-small-cell lung cancer (NSCLC) in adults. It is an option when the tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, and the cancer has not progressed during or after platinum-based chemoradiotherapy. Osimertinib can only be used if the company provides it according to the commercial arrangement.
What this means in practice is that osimertinib must be funded in the NHS in England for the condition and population in the recommendations if it is considered the most suitable treatment option. Osimertinib must be funded in England within 90 days of final publication of this guidance. There is enough evidence to show that osimertinib provides benefits and value for money, so it can be used routinely across the NHS in this population.
For full details and the documents, please see the NICE website”
